| 摘要 |
<p>The present invention relates to famesoid X receptors (FXR, NR1 H4) FXR is a member of the nuclear receptor class of ligand-activated transcription factors More particularly, the present invention relates to compounds useful as agonists for FXR, pharmaceutical formulations comprising such compounds, and therapeutic use of the same Novel isoxazole compounds are disclosed as part of pharmaceutical compositions for the treatment of a condition mediated by decreased FXR activity, such as obesity, diabetes, cholestatic liver disease and metabolic syndrome</p> |
| 申请人 |
SMITHKLINE BEECHAM CORPORATION;DEATON, DAVID, NORMAN;NAVAS, FRANK, III;SPEARING, PAUL, KENNETH |
发明人 |
DEATON, DAVID, NORMAN;NAVAS, FRANK, III;SPEARING, PAUL, KENNETH |
